Blog

Actively Recruiting Studies Brain Cancer (Primary) – Glioma Aadi Bioscience (PDF): A Phase 2, Open-label Study of ABI-009 (nab-Rapamycin) in Bevacizumab-naïve Patients with Recurrent High-grade Glioma and in Patients with Newly Diagnosed Glioblastoma (NCT03463265) Orbus Therapeutics (PDF): A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine...

Drug shows encouraging signs for patients of less common type of dementia. Pacific Neuroscience Institute located at Providence Saint John’s Health Center among sites for clinical trial.

Actively Recruiting Studies Brain Cancer (Primary) – Glioma Aadi Bioscience (PDF): A Phase 2, Open-label Study of ABI-009 (nab-Rapamycin) in Bevacizumab-naïve Patients with Recurrent High-grade Glioma and in Patients with Newly Diagnosed Glioblastoma (NCT03463265) Orbus Therapeutics (PDF): A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine...

Actively Recruiting Studies Brain Cancer (Primary) – Glioma Aadi Bioscience ( PDF ): A Phase 2, Open-label Study of ABI-009 (nab-Rapamycin) in Bevacizumab-naïve Patients with Recurrent High-grade Glioma and in Patients with Newly Diagnosed Glioblastoma ( NCT03463265 ) Orbus Therapeutics ( PDF ): A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine...

Find out about the new and ongoing neuroscience clinical trials at Pacific Neuroscience Institute, addressing difficult diseases such as brain tumors.

Pacific Neuroscience Institute’s Pacific Brain Health Center, an outpatient clinic of the Providence Saint John’s Health Center in Santa Monica, CA, is the site for an IRB approved study from Evoke Neuroscience.

An antiviral and an anti-inflammatory therapy against COVID-19, and convalescent plasma are currently in clinical trials at Providence Saint John’s Health Center in Santa Monica, CA.

A new trial treatment using blood plasma donations from people who have fully recovered from COVID-19 infection may be helpful in treating other patients with COVID-19.

First COVID-19 Patient Treated Under Emergency Use IND At Providence Saint John’s Health Center Using Stemedica Ischemia-Tolerant Allogeneic Mesenchymal Bone Marrow Cells Published: Apr 20, 2020 Originally published: https://www.biospace.com/article/releases/first-covid-19-patient-treated-under-emergency-use-ind-at-providence-saint-john-s-health-center-using-stemedica-ischemia-tolerant-allogeneic-mesenchymal-bone-marrow-cells/ SANTA MONICA, Calif., April 20, 2020 /PRNewswire/ — A single patient, emergency Investigational New Drug (IND) use was...

In February 2020, founder and CEO of Ring, Jamie Siminoff, invited Dr. Santosh Kesari, to speak to top business influencers at a YPO event held in Los Angeles to discuss modern advances in medicine including early detection and prevention of cancer and other neurological diseases, precision medicine,...